Gene: PTPRN2

5799
IA-2beta|IAR|ICAAR|PTPRP|R-PTP-N2
protein tyrosine phosphatase, receptor type N2
protein-coding
7q36.3
Ensembl:ENSG00000155093 MIM:601698 Vega:OTTHUMG00000152646 UniprotKB:Q92932
NG_029966.1
PubMed|SNP Mapped
6   ANCO-SNPs
CD|OD|ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.015e-1 (AD)  6.764e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7801395chr7:158497735 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs11772608chr7:158026633 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs2164220chr7:157962533 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs2241749chr7:157950773 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)
rs1638755chr7:157760120 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs11764539chr7:157666180 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg11900120chr7:158037149PTPRN2Gene body9.135e-5Alcohol use disorders26763658
cg14527439chr7:158266198PTPRN2Gene body1.495e-4Alcohol use disorders26763658
cg09383172chr7:157932921PTPRN2Gene body2.915e-4Alcohol use disorders26763658
cg04087039chr7:157697459PTPRN2Gene body3.161e-4Alcohol use disorders26763658
cg06018853chr7:157696839PTPRN2Gene body4.020e-4Alcohol use disorders26763658
cg21280014chr7:157644665PTPRN2Gene body4.068e-4Alcohol use disorders26763658
cg16561057chr7:157644555PTPRN2Gene body4.577e-4Alcohol use disorders26763658
cg02078164chr7:157982224PTPRN2Gene body5.096e-4Alcohol use disorders26763658
cg22519571chr7:158255029PTPRN2Gene body6.892e-4Alcohol use disorders26763658
cg02223801chr7:157366933PTPRN24.300e-10Smoking27651444
cg05433557chr7:158325024PTPRN22.100e-8Smoking27651444
cg00566158chr7:157461108PTPRN22.500e-8Smoking27651444
cg23385492chr7:158325118PTPRN26.000e-8Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ARHGEF90.962
CALM30.961
DNAJC50.961
GNG30.958
MTA30.956
SPRYD30.953
ATCAY0.951
MAP20.95
CDK5R10.949
SEPT30.949

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.59
OR4F29-0.537
CSAG1-0.5
CLEC2B-0.485
REST-0.476
RAI14-0.47
CNN2-0.465
IL18RAP-0.464
CST7-0.46
NFE2-0.457

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of PTPRN2 mRNA"27291303
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of PTPRN2 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of PTPRN2 mRNA26690555|2906747
D020106AcrylamideAcrylamide results in decreased expression of PTPRN2 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 affects the expression of PTPRN2 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of PTPRN2 mRNA21632981|2164198
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of PTPRN2 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of PTPRN2 mRNA16483693
D001151ArsenicArsenic affects the methylation of PTPRN2 gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of PTPRN2 mRNA26705709
D001280AtrazineAtrazine results in decreased expression of PTPRN2 mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PTPRN2 mRNA20106945|2163298
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PTPRN2 mRNA"26238291
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of PTPRN2 mRNA26496021
C006780bisphenol Abisphenol A affects the expression of PTPRN2 mRNA25181051
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of PTPRN2 mRNA26496021
C006780bisphenol Abisphenol A results in increased methylation of PTPRN2 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of PTPRN2 mRNA26079696
D002509CephaloridineCephaloridine results in increased expression of PTPRN2 mRNA18500788
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of PTPRN2 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of PTPRN2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of PTPRN2 mRNA27392435
D002117CalcitriolCalcitriol results in increased expression of PTPRN2 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of PTPRN2 mRNA21592394
D004610Ellagic AcidEllagic Acid results in increased expression of PTPRN2 mRNA12002526
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of PTPRN2 mRNA23649840
D005557FormaldehydeFormaldehyde results in decreased expression of PTPRN2 mRNA23649840
D019833Genistein[Genistein co-treated with Methoxychlor] results in increased expression of PTPRN2 mRNA21782745
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of PTPRN2 mRNA27392435
D007657Ketone BodiesKetone Bodies results in decreased expression of PTPRN2 mRNA16807920
D008731Methoxychlor[Genistein co-treated with Methoxychlor] results in increased expression of PTPRN2 mRNA21782745
D008731MethoxychlorMethoxychlor results in increased expression of PTPRN2 mRNA21782745
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of PTPRN2 mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PTPRN2 mRNA"20188158
C028007nickel monoxidenickel monoxide results in decreased expression of PTPRN2 mRNA19167457
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of PTPRN2 mRNA26272509
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PTPRN2 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of PTPRN2 mRNA26272509
D010936Plant ExtractsPlant Extracts results in decreased expression of PTPRN2 mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of PTPRN2 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of PTPRN2 mRNA21632981
C059514resveratrolresveratrol results in increased expression of PTPRN2 mRNA12569576
D012822Silicon DioxideSilicon Dioxide analog affects the expression of PTPRN2 mRNA25895662
C017947sodium arsenitesodium arsenite affects the methylation of PTPRN2 gene28589171
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of PTPRN2 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of PTPRN2 mRNA21592394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PTPRN2 mRNA21632981
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PTPRN2 mRNA24680724
D013755Tetradecanoylphorbol Acetate[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of PTPRN2 mRNA16979875
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased methylation of PTPRN2 gene28576685
D014212TretinoinTretinoin results in decreased expression of PTPRN2 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of PTPRN2 mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of PTPRN2 mRNA"26179874
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of PTPRN2 mRNA29024780
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of PTPRN2 mRNA26272509
C025643vinclozolinvinclozolin results in increased expression of PTPRN2 mRNA20566332
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of PTPRN2 mRNA26272509
D015032Zinc[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of PTPRN2 mRNA16979875

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005001transmembrane receptor protein tyrosine phosphatase activity-TAS8798755  
GO ID GO Term Qualifier Evidence PubMed
GO:0006470protein dephosphorylation-TAS8798755  
GO:0006629lipid metabolic process-IEA-  
GO:0007269neurotransmitter secretion-ISS-  
GO:0034260negative regulation of GTPase activity-IEA-  
GO:0035335peptidyl-tyrosine dephosphorylation-IEA-  
GO:0035773insulin secretion involved in cellular response to glucose stimulus-ISS-  
GO:0043312neutrophil degranulation-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005788endoplasmic reticulum lumen-IEA-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-TAS8798755  
GO:0030054cell junction-IEA-  
GO:0030667secretory granule membrane-ISS-  
GO:0030672synaptic vesicle membrane-ISS-  
GO:0043195terminal bouton-IEA-  
GO:0043235receptor complex-IDA23382219  
GO:0101003ficolin-1-rich granule membrane-TAS-  
KEGG ID KEGG Term
hsa04940Type I diabetes mellitus
Reactome ID Reactome Term Evidence
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-6798695Neutrophil degranulationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21849985A genomewide linkage scan of cocaine dependence and major depressive episode in two populations. (2011 Nov)Yang BZNeuropsychopharmacology
29459480Occupational exposure to pesticides is associated with differential DNA methylation. (2018 Jun)van der Plaat DAOccup Environ Med
29315717Impact of cigarette-smoking on sperm DNA methylation and its effect on sperm parameters. (2018 Jan 9)Alkhaled YAndrologia